Jack Gemmell

This inventor holds 11 USPTO granted patents, plus 2 CIPO patents and 1 EPO patent. Top assignees: Nymox Corporation, Nymox Pharmaceutical Corporation, Qualcomm Incorporated. Active years: 2002-2016.

USPTO Granted Patents = 11

% Patents Active = 54.5

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 2.0

ph-index = 8

Forward Citations = 382(Granted Patents)

Company Filing History:

Nymox Pharmaceutical Corporation

patents

1 out of 44,749

Qualcomm Incorporated

patents

Years Active: 2002-2016

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9243035 - Peptides effective in the treatment of conditions requiring the removal or destruction of cells (2016-01-26),

2. 8716247 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2014-05-06),

3. 8569446 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2013-10-29),

4. 8293703 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2012-10-23),

5. 8067378 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2011-11-29),

6. 7745572 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2010-06-29),

7. 7544771 - Protein and its use in diagnosing Alzheimer's disease (2009-06-09),

8. 7408021 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2008-08-05),

9. 7317077 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2008-01-08),

10. 7241738 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2007-07-10),

11. 6461608 - Bacteriophage composition useful in treating food products to prevent bacterial contamination (2002-10-08),

Title: Jack Gemmell: Innovator in Peptide Therapeutics

Introduction

Jack Gemmell is a notable inventor based in Mississauga, Canada, recognized for his contributions to the field of peptide therapeutics. With a total of 11 patents to his name, Gemmell has made significant strides in developing innovative treatments for conditions that require the removal or destruction of harmful cells.

Latest Patents

Among his latest patents, Gemmell has focused on peptides that are effective in treating conditions necessitating the removal or destruction of cells. One of his notable inventions involves peptides, compositions, and methods aimed at treating benign and malignant tumors. This patent outlines the use of compounds based on peptides to address these medical challenges. Another significant patent details methods for treating conditions that require the destruction of cellular elements, including tumors in humans. The methods described include various administration routes such as intramuscularly, orally, intravenously, and more, either alone or conjugated to a carrier.

Career Highlights

Throughout his career, Jack Gemmell has worked with prominent companies in the pharmaceutical sector, including Nymox Pharmaceutical Corporation and Nymox Corporation. His work has contributed to advancements in medical treatments, particularly in oncology and cell therapy.

Collaborations

Gemmell has collaborated with various professionals in his field, including his coworker Paul A. Averback. Their joint efforts have furthered the development of innovative therapeutic solutions.

Conclusion

Jack Gemmell's work in peptide therapeutics showcases his dedication to advancing medical science and improving patient outcomes. His innovative patents reflect a commitment to addressing critical health challenges through cutting-edge research and development.